Motohiro Hirao

Motohiro Hirao

Auto-generated profile, based on publicly available information

Motohiro Hirao

Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2011
Verified
Journal Article
Closed access
HOHisataka Ogawa
Hisataka Ogawa
KFKazumasa Fujitani
Kazumasa Fujitani
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
KIKenji Imanishi
Kenji Imanishi
HSHatsumi Shirakata
Hatsumi Shirakata
SUShigetoshi Utsumi
Shigetoshi Utsumi

14 September 2011 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MHM. Hirao
M. Hirao
NAN. Ando
N. Ando
TTT. Tsujinaka
T. Tsujinaka
HUH. Udagawa
H. Udagawa
MYM. Yano
M. Yano
OGon behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group
on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group

16 June 2005 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MHMotohiro Hirao
Motohiro Hirao
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
ATAtsushi Takeno
Atsushi Takeno
KFKazumasa Fujitani
Kazumasa Fujitani
MKMiki Kurata
Miki Kurata

11 July 2012 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
O(Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)
MHMotohiro Hirao
Motohiro Hirao
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
HIHiroshi Imamura
Hiroshi Imamura
YKYukinori Kurokawa
Yukinori Kurokawa
HFHiroshi Furukawa
Hiroshi Furukawa

13 December 2006
Verified
Journal Article
Closed access
TMTomoki Makino
Tomoki Makino
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
HMHideuki Mishima
Hideuki Mishima
MIMasakazu Ikenaga
Masakazu Ikenaga
TSToshiro Sawamura
Toshiro Sawamura
MMMasayuki Mano
Masayuki Mano

20 January 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HTHiroya Takeuchi
Hiroya Takeuchi
JMJunki Mizusawa
Junki Mizusawa
KKKen Kato
Ken Kato
KKKozo Kataoka
Kozo Kataoka
HIHiroyasu Igaki
Hiroyasu Igaki
YKYuko Kitagawa
Yuko Kitagawa
155 Background: Although the impact of postoperative complications, especially infectious complications (IC), on long-term survival after transthoracic esophagectomy remains controversial to date, we hypothesized that postoperative IC may affect tumor recurrence and survival of the patients (pts) undergoing transthoracic esophagectomy. Methods: The data from JCOG9907 (Ando N; Ann Surg Oncol 2012) was used to estimate the influence of IC on the outcome of current standard preoperative chemotherapy followed by surgery for clinical stage II/III squamous cell carcinoma of the thoracic esophagus. IC were classified into three: pneumonia, anastomotic leakage, and the others. OS and PFS were estimated by landmark method at 6 months from randomization. Univariate and multivariate analyses using Cox proportional hazard model were performed to assess the impact of postoperative complications on the survival after right-transthoracic esophagectomy with extended lymphadenectomy. Results: Among the 152 analyzed pts, the incidence of overall IC was 36%, among which pneumonia and anastomotic leakage were observed both in 14%. OS of pts with any IC (n=54) was shorter than that of pts without IC (HR 1.66, 95%CI [1.02-2.71]) and PFS also tended to be shorter in pts with any IC (HR 1.44, [0.92-2.23]). OS of pts with pneumonia (n=22) was shorter than that of pts without pneumonia (HR 1.82, [1.01-3.29]), and PFS also tended to be shorter in pts with pneumonia (HR 1.50, [0.85-2.62]). OS of pts with anastomotic leakage (n=21) were nearly identical to that for pts without leakage (HR 1.06, [0.52-2.13]) and PFS was slightly shorter in pts with leakage (HR 1.28, [0.71-2.32]). Multivariate analysis revealed that pneumonia tended to compromise OS and PFS (HR 1.66, [0.87-3.17] and HR 1.37, [0.75-2.51]). Conclusions: This study reveals that postoperative morbidity, especially pneumonia may deteriorate the survival of pts undergoing esophagectomy after preoperative chemotherapy. Achieving esophagectomy without postoperative complications might prolong OS and PFS. Clinical trial information: NCT00190554.